EMBO Molecular Medicine (EMM), one of five journals published by EMBO Press, was established in 2009 for the purpose of publishing the best work at the interface between clinical research and molecular cell biology. In its tenth anniversary year, we highlight ten characteristics that have helped to establish EMM in the world of scientific publishing.
Multi-journal partnership aims to accelerate scientific publishing by offering journal-independent peer review
Nine life scientists join the new EMBO Programme in its first year
MALT1 blockers have long been in clinical use for the treatment of blood cancers. A study suggests that these drugs could potentially also be developed as a treatment option for glioblastoma, the most common and lethal type of brain tumour.
EMBO Press is pleased to announce the appointment of systems biologist M. Madan Babu as the new Chief Editor of Molecular Systems Biology.
The annual EMBO Members’ Meeting took place from 29-31 October 2019 in Heidelberg, Germany, and welcomed 53 recently elected members, who presented their work in talks and were able to meet each other and find out more about EMBO.
EMBO congratulates twenty-seven life scientists on their selection as new EMBO Young Investigators.
The Israeli Acute Paralysis Virus is a pathogen that affects honey bees and has been linked to Colony Collapse Disorder, a key factor in decimating the bee population.
There are many indications that fasting promotes longevity. In recent years, much attention has been devoted to so-called caloric restriction mimetics (CMRs), substances that simulate the health-promoting effects of fasting without the need of life-style change.
Salaried employment, contributions to social security schemes, leadership training and networking